Nxstage Medical Earnings: Here’s Why Investors are Buying Shares Now

Nxstage Medical, Inc. (NASDAQ:NXTM) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 5.53%.

Nxstage Medical, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.04 in the quarter versus EPS of $-0.08 in the year-earlier quarter.

Revenue: Rose 14% to $65 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Nxstage Medical, Inc. reported adjusted EPS loss of $0.04 per share. By that measure, the company beat the mean analyst estimate of $-0.05. It beat the average revenue estimate of $63.54 million.

Quoting Management: “As evidenced by our 2012 results, our business and market fundamentals remain strong and positive. We believe NxStage is uniquely positioned for growth as it continues to make a difference to people’s lives with significant innovations that are advancing the standard of renal care,” stated Jeffrey H. Burbank, Founder and Chief Executive Officer.

Key Stats (on next page)…